Airis Pharma is a scientifically driven execution partner focused on complex, high-barrier generics. We operate at the intersection of analytical rigor, IP navigation, and bioequivalence confidence to unlock molecules others choose not to pursue.
Three disciplines, executed by seasoned scientists who own complex generic programs end-to-end — from molecule selection to regulatory approval.
Quality-by-Design applied selectively to de-risk formulation, scale-up, and BE performance — translating R&D complexity into predictable, regulator-ready outcomes.
Proven track record executing complex Paragraph IV, NCE-1, and non-infringing development strategies across USFDA, MHRA, Health Canada, and select emerging markets.
Deep hands-on experience delivering complex dossiers with a focus on regulator-quiet approvals — minimizing review cycles, maximizing predictability.
Aurobindo, Biocon, MSN and other leading developers partner with Airis for the dossiers that have to land cleanly the first time.